US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
US6822267B1
(en)
*
|
1997-08-20 |
2004-11-23 |
Advantest Corporation |
Signal transmission circuit, CMOS semiconductor device, and circuit board
|
PT1233958E
(pt)
|
1999-11-23 |
2011-09-20 |
Methylgene Inc |
Inibidores de histona desacetilase
|
US20030129724A1
(en)
|
2000-03-03 |
2003-07-10 |
Grozinger Christina M. |
Class II human histone deacetylases, and uses related thereto
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
WO2002026696A1
(en)
|
2000-09-29 |
2002-04-04 |
Prolifix Limited |
Carbamic acid compounds comprising an amide linkage as hdac inhibitors
|
US7312247B2
(en)
*
|
2001-03-27 |
2007-12-25 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
ATE517624T1
(de)
*
|
2001-10-16 |
2011-08-15 |
Sloan Kettering Inst Cancer |
Behandlung von neurodegenerativen erkrankungen und krebs im gehirn
|
US7402603B2
(en)
*
|
2001-11-06 |
2008-07-22 |
Novartis Ag |
Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
|
US7456219B2
(en)
|
2002-03-04 |
2008-11-25 |
Merck Hdac Research, Llc |
Polymorphs of suberoylanilide hydroxamic acid
|
BR0308250A
(pt)
|
2002-03-04 |
2005-01-11 |
Aton Pharma Inc |
Métodos de indução de diferenciação terminal
|
US7148257B2
(en)
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
US7629343B2
(en)
|
2002-04-03 |
2009-12-08 |
Topotarget Uk Limited |
Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
|
US7495022B2
(en)
|
2002-04-11 |
2009-02-24 |
Sk Chemicals Co., Ltd. |
α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
|
EP1501489A4
(en)
*
|
2002-04-15 |
2007-11-21 |
Sloan Kettering Inst Cancer |
COMBINATION THERAPY FOR THE TREATMENT OF CANCER
|
EP1515750B1
(en)
*
|
2002-06-10 |
2010-08-11 |
Novartis AG |
Combinations comprising epothilones and pharmaceutical uses thereof
|
CA2495354A1
(en)
*
|
2002-08-20 |
2004-03-04 |
Yamanouchi Pharmaceutical Co., Ltd. |
An agent for inhibiting articular cartilage extracellular matrix degradation
|
US20060100140A1
(en)
*
|
2002-09-13 |
2006-05-11 |
Paul Dent |
Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]2-methylphenyl}-4- (3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
|
US7154002B1
(en)
|
2002-10-08 |
2006-12-26 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
US7250514B1
(en)
|
2002-10-21 |
2007-07-31 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
EP1562898A1
(en)
*
|
2002-11-19 |
2005-08-17 |
Takeda Pharmaceutical Company Limited |
Indole derivatives as somatostatin agonists or antagonists
|
AU2003296310A1
(en)
|
2002-12-06 |
2004-06-30 |
University Of South Florida |
Histone deacetylase inhibitor enhancement of trail-induced apoptosis
|
TW200418806A
(en)
|
2003-01-13 |
2004-10-01 |
Fujisawa Pharmaceutical Co |
HDAC inhibitor
|
EP1583736A1
(en)
|
2003-01-17 |
2005-10-12 |
TopoTarget UK Limited |
Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
|
AU2003900587A0
(en)
*
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
AU2003900608A0
(en)
*
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
EP1599449A2
(en)
|
2003-02-25 |
2005-11-30 |
TopoTarget UK Limited |
Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors
|
CA2518318A1
(en)
|
2003-03-17 |
2004-09-30 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
MXPA05012464A
(es)
*
|
2003-05-21 |
2006-01-30 |
Novartis Ag |
Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.
|
WO2005011598A2
(en)
*
|
2003-07-31 |
2005-02-10 |
University Of South Florida |
Leukemia treatment method and composition
|
WO2005013958A1
(en)
*
|
2003-08-07 |
2005-02-17 |
Novartis Ag |
Histone deacetylase inhibitors as immunosuppressants
|
CA2533861A1
(en)
|
2003-08-08 |
2005-02-17 |
Novartis Ag |
Combinations comprising staurosporines
|
JP4338734B2
(ja)
|
2003-08-26 |
2009-10-07 |
メルク エイチディーエーシー リサーチ エルエルシー |
Hdac阻害剤による癌処置法
|
EP1667680A4
(en)
|
2003-08-29 |
2008-10-08 |
Aton Pharma Inc |
COMBINED METHODS OF TREATING CANCER
|
CN100455564C
(zh)
*
|
2003-09-12 |
2009-01-28 |
深圳微芯生物科技有限责任公司 |
组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
|
WO2005025619A1
(en)
*
|
2003-09-18 |
2005-03-24 |
Novartis Ag |
Combination of a histone deacetylase inhibitor with a death receptor ligand
|
EP1673349B1
(en)
*
|
2003-09-22 |
2010-06-30 |
S*Bio Pte Ltd |
Benzimidazole derivatives: preparation and pharmaceutical applications
|
DK1673349T3
(da)
|
2003-09-22 |
2010-10-25 |
S Bio Pte Ltd |
Benzimidazolderivater: fremstilling og farmaceutiske anvendelser
|
CA2537991A1
(en)
*
|
2003-09-23 |
2005-03-31 |
Novartis Ag |
Combination of a vegf receptor inhibitor with a chemotherapeutic agent
|
TW200524575A
(en)
*
|
2003-10-27 |
2005-08-01 |
S Bio Pte Ltd |
Biaryl linked hydroxamates: preparation and pharmaceutical applications
|
JP5107579B2
(ja)
*
|
2003-12-02 |
2012-12-26 |
ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション |
新規の種類のヒストン脱アセチル化酵素阻害剤としてのZn2+キレートモチーフ係留短鎖脂肪酸
|
EP1541549A1
(en)
|
2003-12-12 |
2005-06-15 |
Exonhit Therapeutics S.A. |
Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
|
WO2005066151A2
(en)
*
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
WO2005065681A1
(en)
*
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
|
US20050197336A1
(en)
*
|
2004-03-08 |
2005-09-08 |
Miikana Therapeutics Corporation |
Inhibitors of histone deacetylase
|
US7345043B2
(en)
*
|
2004-04-01 |
2008-03-18 |
Miikana Therapeutics |
Inhibitors of histone deacetylase
|
KR20080083220A
(ko)
|
2004-04-07 |
2008-09-16 |
노파르티스 아게 |
Iap 억제제
|
JP2008506776A
(ja)
*
|
2004-07-19 |
2008-03-06 |
メルク エンド カムパニー インコーポレーテッド |
ヒストン脱アセチル化酵素阻害剤
|
EP1776357A1
(en)
*
|
2004-08-09 |
2007-04-25 |
Astellas Pharma Inc. |
Hydroxyamide compounds having activity as inhibitors of histone deacetylase (hdac)
|
ITMI20041869A1
(it)
|
2004-10-01 |
2005-01-01 |
Dac Srl |
Nuovi inibitori delle istone deacetilasi
|
US8242175B2
(en)
|
2004-10-01 |
2012-08-14 |
Dac S.R.L. |
Class of histone deacetylase inhibitors
|
US7235688B1
(en)
|
2004-11-04 |
2007-06-26 |
University Of Notre Dame Du Lac |
Process for preparing histone deacetylase inhibitors and intermediates thereof
|
US20070021612A1
(en)
*
|
2004-11-04 |
2007-01-25 |
University Of Notre Dame Du Lac |
Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
|
WO2006066133A2
(en)
*
|
2004-12-16 |
2006-06-22 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
EP1851219A1
(en)
|
2005-02-14 |
2007-11-07 |
Miikana Therapeutics, Inc. |
Fused heterocyclic compounds useful as inhibitors of histone deacetylase
|
US7666880B2
(en)
*
|
2005-03-21 |
2010-02-23 |
S*Bio Pte Ltd. |
Imidazo[1,2-A]pyridine derivatives: preparation and pharmaceutical applications
|
CA2601706C
(en)
|
2005-03-22 |
2016-09-20 |
Dana-Farber Cancer Institute, Inc. |
Treatment of protein degradation disorders
|
GB0509225D0
(en)
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Inhibitors of enzymatic activity
|
GB0509223D0
(en)
*
|
2005-05-05 |
2005-06-15 |
Chroma Therapeutics Ltd |
Enzyme inhibitors
|
US7642253B2
(en)
*
|
2005-05-11 |
2010-01-05 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
TWI415603B
(zh)
|
2005-05-20 |
2013-11-21 |
Merck Sharp & Dohme |
1,8-辛二醯基苯胺羥胺酸(suberoylanilide hydroxamic acid)之調配物及其製配方法
|
EA200800321A1
(ru)
*
|
2005-07-14 |
2008-06-30 |
Такеда Сан Диего, Инк. |
Ингибиторы гистондеацетилазы
|
WO2007016532A2
(en)
*
|
2005-08-02 |
2007-02-08 |
Novartis Ag |
Mutations and polymorphisms of hdac4
|
MX2008001610A
(es)
*
|
2005-08-03 |
2008-02-19 |
Novartis Ag |
Uso de inhibidores de hdac para el tratamiento de mieloma.
|
RU2008108909A
(ru)
*
|
2005-08-10 |
2009-09-20 |
Новартис АГ (CH) |
Способ применения ингибиторов деацетилазы
|
JP2009504674A
(ja)
*
|
2005-08-11 |
2009-02-05 |
ノバルティス アクチエンゲゼルシャフト |
有機化合物の組合せ
|
EP2275096A3
(en)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenesis via modulation of the muscarinic receptors
|
AU2006284403A1
(en)
*
|
2005-08-26 |
2007-03-01 |
Methylgene Inc. |
Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
|
EP2258357A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
WO2007030455A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Novartis Ag |
Mutations and polymorphisms of hdac10
|
WO2007030454A2
(en)
*
|
2005-09-07 |
2007-03-15 |
Novartis Ag |
Mutations and polymorphisms of hdac9
|
WO2007038073A2
(en)
*
|
2005-09-22 |
2007-04-05 |
Novartis Ag |
Mutations and polymorphisms of hdac11
|
EP1996550A2
(en)
|
2005-09-27 |
2008-12-03 |
Novartis AG |
Carboxyamine compounds and their use in the treatment of hdac dependent diseases
|
WO2007047998A2
(en)
*
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Mutations and polymorphisms of hdac2
|
WO2007047978A2
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
CA2625966A1
(en)
|
2005-10-24 |
2007-05-03 |
Novartis Ag |
Combination of histone deacetylase inhibitors and radiation
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
WO2007053502A2
(en)
*
|
2005-11-01 |
2007-05-10 |
Novartis Ag |
Mutations and polymorphisms of hdac5
|
WO2007058992A2
(en)
*
|
2005-11-14 |
2007-05-24 |
Novartis Ag |
Mutations and polymorphisms of hdac6
|
BRPI0618808A2
(pt)
|
2005-11-21 |
2011-09-13 |
Novartis Ag |
uso de um inibidor de mtor
|
US20070207950A1
(en)
*
|
2005-12-21 |
2007-09-06 |
Duke University |
Methods and compositions for regulating HDAC6 activity
|
EP1976835A2
(en)
*
|
2006-01-13 |
2008-10-08 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
WO2007091703A1
(en)
|
2006-02-07 |
2007-08-16 |
Astellas Pharma Inc. |
N-hydroxyacrylamide compounds
|
JP5441416B2
(ja)
*
|
2006-02-14 |
2014-03-12 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
二官能性ヒストンデアセチラーゼインヒビター
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
WO2007124252A2
(en)
|
2006-04-05 |
2007-11-01 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
CA2644143C
(en)
|
2006-04-05 |
2013-10-01 |
Novartis Ag |
Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
|
EP2447360A1
(en)
|
2006-04-14 |
2012-05-02 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
US8168383B2
(en)
|
2006-04-14 |
2012-05-01 |
Cell Signaling Technology, Inc. |
Gene defects and mutant ALK kinase in human solid tumors
|
US9539303B2
(en)
|
2006-04-24 |
2017-01-10 |
Celgene Corporation |
Treatment of Ras-expressing tumors
|
US20090018142A9
(en)
*
|
2006-05-02 |
2009-01-15 |
Zhengping Zhuang |
Use of phosphatases to treat tumors overexpressing N-CoR
|
AU2007249435A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
JP2009536669A
(ja)
|
2006-05-09 |
2009-10-15 |
ブレインセルス,インコーポレイティド |
アンジオテンシン調節による神経新生
|
CN101443002B
(zh)
|
2006-05-09 |
2012-03-21 |
诺瓦提斯公司 |
包含铁螯合剂和抗肿瘤药的组合及其用途
|
US8957027B2
(en)
|
2006-06-08 |
2015-02-17 |
Celgene Corporation |
Deacetylase inhibitor therapy
|
CN102174008A
(zh)
*
|
2006-06-12 |
2011-09-07 |
诺瓦提斯公司 |
一种制备2-甲基色胺的方法
|
JP2009540006A
(ja)
*
|
2006-06-12 |
2009-11-19 |
ノバルティス アクチエンゲゼルシャフト |
N−ヒドロキシ−3−[4−[[[2−(2−メチル−1h−インドール−3−イル)エチル]アミノ]メチル]フェニル]−2e−2−プロペンアミドの多形
|
CN101466672B
(zh)
*
|
2006-06-12 |
2012-05-16 |
诺瓦提斯公司 |
N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐
|
BRPI0712771A2
(pt)
*
|
2006-06-12 |
2012-09-25 |
Novartis Ag |
sais de n-hidróxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino] metil]fenil]-2e-2-propenamida
|
CA2654230C
(en)
|
2006-06-12 |
2012-09-11 |
Novartis Ag |
Process for making a lactate salt of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
|
CN101478959A
(zh)
*
|
2006-06-26 |
2009-07-08 |
诺瓦提斯公司 |
有机化合物
|
KR20090064418A
(ko)
|
2006-09-08 |
2009-06-18 |
브레인셀즈 인코퍼레이션 |
4-아실아미노피리딘 유도체 포함 조합물
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
WO2008036046A1
(en)
|
2006-09-20 |
2008-03-27 |
S*Bio Pte Ltd |
IMIDAZO[l,2-a]PYRIDINE HYDROXYMATE COMPOUNDS THAT ARE INHIBITORS OF HISTONE DEACETYLASE
|
EP2079304A4
(en)
*
|
2006-09-28 |
2010-01-06 |
Merck & Co Inc |
AMINBASE SALTS FROM SAHA AND POLYMORPHE DAVON
|
JP2010504933A
(ja)
|
2006-09-29 |
2010-02-18 |
ノバルティス アーゲー |
Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
|
GB0619753D0
(en)
*
|
2006-10-06 |
2006-11-15 |
Chroma Therapeutics Ltd |
Enzyme inhibitors
|
EP2077999B1
(en)
|
2006-10-30 |
2014-07-30 |
Chroma Therapeutics Limited |
Hydroxamates as inhibitors of histone deacetylase
|
WO2008058287A1
(en)
*
|
2006-11-10 |
2008-05-15 |
Syndax Pharmaceuticals, Inc. |
COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
|
RU2469717C2
(ru)
*
|
2006-12-04 |
2012-12-20 |
Новартис Аг |
Комбинация ингибитора гда и антиметаболита
|
KR20090099561A
(ko)
*
|
2006-12-15 |
2009-09-22 |
아스텔라스세이야쿠 가부시키가이샤 |
N-히드록시아크릴아미드 화합물
|
AU2008204928B2
(en)
*
|
2007-01-10 |
2011-03-31 |
Novartis Ag |
Formulations of deacetylase inhibitors
|
CN101662939B
(zh)
|
2007-02-06 |
2015-11-25 |
利克斯特生物技术公司 |
氧杂双环庚烷和氧杂双环庚烯,它们的制备及用途
|
CN101626758A
(zh)
|
2007-02-15 |
2010-01-13 |
诺瓦提斯公司 |
用于治疗癌症的lbh589和其他治疗剂的组合
|
KR20090125209A
(ko)
|
2007-03-28 |
2009-12-03 |
산텐 세이야꾸 가부시키가이샤 |
히스톤 탈아세틸화 효소 저해 작용을 갖는 화합물을 유효 성분으로서 함유하는 안압 하강제
|
JP5746860B2
(ja)
*
|
2007-04-09 |
2015-07-08 |
メチルジーン インコーポレイテッド |
ヒストンデアセチラーゼ阻害剤
|
AU2008247603A1
(en)
*
|
2007-05-04 |
2008-11-13 |
Novartis Ag |
Use of HDAC inhibitors for the treatment of gastrointestinal cancers
|
US20110034531A1
(en)
*
|
2007-05-11 |
2011-02-10 |
Novartis Ag |
Use of hdac inhibitors for the treatment of melanoma
|
ES2726401T3
(es)
*
|
2007-05-30 |
2019-10-04 |
Novartis Ag |
Uso de inhibidores de HDAC para el tratamiento de la destrucción ósea
|
US7737175B2
(en)
|
2007-06-01 |
2010-06-15 |
Duke University |
Methods and compositions for regulating HDAC4 activity
|
US20090035292A1
(en)
*
|
2007-08-03 |
2009-02-05 |
Kovach John S |
Use of phosphatases to treat neuroblastomas and medulloblastomas
|
CL2008002786A1
(es)
*
|
2007-09-20 |
2009-05-15 |
Novartis Ag |
Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
|
CA2700857C
(en)
|
2007-10-01 |
2016-08-02 |
John S. Kovach |
Hdac inhibitors
|
NZ584845A
(en)
*
|
2007-10-22 |
2011-09-30 |
Orchid Res Lab Ltd |
Histone deacetylase inhibitors
|
CN101417967A
(zh)
*
|
2007-10-26 |
2009-04-29 |
浙江海正药业股份有限公司 |
组蛋白去乙酰酶抑制剂、其组合物及其应用
|
WO2009067453A1
(en)
*
|
2007-11-19 |
2009-05-28 |
Syndax Pharmaceuticals, Inc. |
Combinations of hdac inhibitors and proteasome inhibitors
|
US20110044952A1
(en)
*
|
2007-11-27 |
2011-02-24 |
Ottawa Health Research Institute |
Amplification of cancer-specific oncolytic viral infection by histone deacetylase inhibitors
|
AU2008350907A1
(en)
|
2007-12-11 |
2009-08-27 |
Viamet Pharmaceuticals, Inc. |
Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
|
ITFI20070288A1
(it)
|
2007-12-21 |
2009-06-22 |
A I L Firenze Sezione Autonoma |
Inibitori delle deacetilasi istoniche
|
EP2100879A1
(en)
*
|
2008-03-13 |
2009-09-16 |
4Sc Ag |
Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds
|
CA2719457C
(en)
|
2008-03-24 |
2017-05-02 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
AU2009228778B2
(en)
|
2008-03-26 |
2012-04-19 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases B
|
WO2010009280A1
(en)
*
|
2008-07-18 |
2010-01-21 |
Novartis Ag |
Use of hdac inhibitors for the treatment of hodgkin's disease
|
JP5665740B2
(ja)
|
2008-07-23 |
2015-02-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
デアセチラーゼ阻害剤およびその使用
|
US8227473B2
(en)
*
|
2008-08-01 |
2012-07-24 |
Lixte Biotechnology, Inc. |
Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
|
WO2010147612A1
(en)
|
2009-06-18 |
2010-12-23 |
Lixte Biotechnology, Inc. |
Methods of modulating cell regulation by inhibiting p53
|
EP2318005B1
(en)
|
2008-08-01 |
2017-11-01 |
Lixte Biotechnology, Inc. |
Neuroprotective agents for the prevention and treatment of neurodegenerative diseases
|
WO2010014141A1
(en)
*
|
2008-08-01 |
2010-02-04 |
Lixte Biotechnology, Inc. |
Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
GB0903480D0
(en)
|
2009-02-27 |
2009-04-08 |
Chroma Therapeutics Ltd |
Enzyme Inhibitors
|
KR101168801B1
(ko)
|
2009-03-27 |
2012-07-25 |
주식회사종근당 |
신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
|
ES2473792T3
(es)
|
2009-04-03 |
2014-07-07 |
Naturewise Biotech & Medicals Corporation |
Compuestos cin�micos y derivados de los mismos para la inhibición de la histona desacetilasa
|
US7994357B2
(en)
|
2009-04-03 |
2011-08-09 |
Naturewise Biotech & Medicals Corporation |
Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase
|
WO2011006908A2
(en)
|
2009-07-16 |
2011-01-20 |
Royal College Of Surgeons In Ireland |
Metal complexes having dual histone deacetylase inhibitory and dna-binding activity
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
US8716344B2
(en)
|
2009-08-11 |
2014-05-06 |
President And Fellows Of Harvard College |
Class- and isoform-specific HDAC inhibitors and uses thereof
|
MX2012001838A
(es)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
|
CA2771532C
(en)
|
2009-08-17 |
2021-03-23 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
BR112012008061A2
(pt)
|
2009-08-20 |
2016-03-01 |
Novartis Ag |
compostos de oxima heterocíclica
|
WO2011023677A1
(en)
|
2009-08-26 |
2011-03-03 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
US20110053925A1
(en)
*
|
2009-08-28 |
2011-03-03 |
Novartis Ag |
Hydroxamate-Based Inhibitors of Deacetylases
|
JP5466767B2
(ja)
|
2009-11-04 |
2014-04-09 |
ノバルティス アーゲー |
Mek阻害剤として有用なヘテロ環式スルホンアミド誘導体
|
JP6220126B2
(ja)
|
2009-11-23 |
2017-10-25 |
セルリアン・ファーマ・インコーポレイテッド |
治療的送達のためのシクロデキストリンに基づく重合体
|
EP2509964B1
(en)
|
2009-12-08 |
2014-04-30 |
Novartis AG |
Heterocyclic sulfonamide derivatives
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
EP2638009A4
(en)
*
|
2010-01-08 |
2014-06-11 |
Harvard College |
FLUORINATED HDAC HEMMER AND USES THEREOF
|
EP2523664A4
(en)
|
2010-01-13 |
2013-06-26 |
Tempero Pharmaceuticals Inc |
COMPOUNDS AND METHODS
|
US8901156B2
(en)
|
2010-01-13 |
2014-12-02 |
Tempero Pharmaceuticals, Inc. |
Compounds and methods
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
US8217079B2
(en)
|
2010-03-26 |
2012-07-10 |
Italfarmaco Spa |
Method for treating Philadelphia-negative myeloproliferative syndromes
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
EP2407164A1
(en)
|
2010-07-14 |
2012-01-18 |
Dublin Institute of Technology Intellectual Property Ltd |
Copper II complexes of phenanthroline and their use in cancer treatment
|
WO2012025701A1
(en)
*
|
2010-08-25 |
2012-03-01 |
Chroma Therapeutics Ltd. |
Alpha, alpha - di substituted glycine ester derivatives and their use as hdac inhibitors
|
WO2012025155A1
(en)
*
|
2010-08-26 |
2012-03-01 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases
|
CA2807738A1
(en)
*
|
2010-08-27 |
2012-03-01 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
EP2651917A1
(en)
|
2010-12-13 |
2013-10-23 |
Novartis AG |
Dimeric iap inhibitors
|
US8703941B2
(en)
|
2011-01-10 |
2014-04-22 |
Nimbus Iris, Inc. |
IRAK inhibitors and uses thereof
|
TW201245115A
(en)
|
2011-01-24 |
2012-11-16 |
Chdi Foundation Inc |
Histone deacetylase inhibitors and compositions and methods of use thereof
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
HUE053300T2
(hu)
|
2011-03-09 |
2021-06-28 |
Cereno Scient Ab |
Vegyületek és eljárások károsodott endogén fibrinolízis javításához hiszton-deacetiláz inhibitorok használatával
|
BR112013031201A2
(pt)
|
2011-06-09 |
2017-01-31 |
Novartis Ag |
derivados de sulfonamida heterocíclicos, composição farmacêutica os compreendendo, uso, processo para a fabricação de (r)-n-(4,5-difluoro-6-((2-fluoro-4-iodofenil)amino)benzofuran-7-il)-1-(2,3-di-idroxipropil)ciclopropano-5 1-sulfonamida e kit
|
EP2720696B1
(en)
|
2011-06-14 |
2016-05-25 |
Novartis AG |
Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
EP2723740A1
(en)
|
2011-06-27 |
2014-04-30 |
Novartis AG |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
CA2848809A1
(en)
|
2011-09-15 |
2013-03-21 |
Novartis Ag |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
|
AU2012335663B2
(en)
|
2011-11-11 |
2015-12-24 |
Array Biopharma Inc. |
Method of treating a proliferative disease
|
US9387208B2
(en)
|
2011-11-23 |
2016-07-12 |
Novartis Ag |
Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
|
CN103130673B
(zh)
*
|
2011-11-28 |
2017-05-03 |
重庆医药工业研究院有限责任公司 |
一种阿戈美拉晶型i的制备方法
|
CN104080787B
(zh)
|
2011-11-29 |
2016-09-14 |
诺华股份有限公司 |
吡唑并吡咯烷化合物
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
JP5903499B2
(ja)
|
2011-12-22 |
2016-04-13 |
ノバルティス アーゲー |
ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
CA2859873A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
WO2013096055A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
BR112014015339A2
(pt)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compostos para inibição da interação de bcl2 com parceiros de ligação
|
AU2012355623A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
MX2014007729A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
AU2012362726A1
(en)
*
|
2011-12-29 |
2014-07-24 |
Pharmacyclics Llc |
Cinnamic acid hydroxyamides as inhibitors of histone deacetylase 8
|
RU2666530C2
(ru)
|
2012-01-12 |
2018-09-11 |
Йейл Юниверсити |
Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
AR092790A1
(es)
*
|
2012-02-01 |
2015-05-06 |
Euro Celtique Sa |
Derivados bencimidazolicos del acido hidroxamico
|
AU2013243097A1
(en)
|
2012-04-03 |
2014-10-09 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
CA2871715A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
MA37519B1
(fr)
|
2012-05-15 |
2017-03-31 |
Novartis Ag |
Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
|
BR112014027584B1
(pt)
|
2012-05-15 |
2023-01-24 |
Novartis Ag |
Uso de inibidores da atividade de abl1, abl2 e bcr-abl1, e composição farmacêutica
|
WO2013171640A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
CN104582732A
(zh)
|
2012-06-15 |
2015-04-29 |
布里格姆及妇女医院股份有限公司 |
治疗癌症的组合物及其制造方法
|
TW201408628A
(zh)
|
2012-07-16 |
2014-03-01 |
Chdi Foundation Inc |
組蛋白去乙醯酶抑制劑及組成物,暨其使用之方法
|
WO2014025395A1
(en)
|
2012-08-06 |
2014-02-13 |
Duke University |
Compounds and methods for targeting hsp90
|
DK2903968T3
(en)
|
2012-10-02 |
2017-01-30 |
Gilead Sciences Inc |
INHIBITORS OF HISTON DEMETHYLASES
|
US20150258068A1
(en)
|
2012-10-30 |
2015-09-17 |
Mei Pharma, Inc. |
Combination therapies
|
CN110787285A
(zh)
|
2012-11-05 |
2020-02-14 |
达纳-法伯癌症研究所股份有限公司 |
Xbp1、cd138和cs1肽、包括所述肽的药物组合物及使用所述肽和组合物的方法
|
US20150283136A1
(en)
|
2012-11-08 |
2015-10-08 |
Novartis Ag |
Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
EP2948453B1
(en)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
EP2948451B1
(en)
|
2013-01-22 |
2017-07-12 |
Novartis AG |
Substituted purinone compounds
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
MD20150085A2
(ro)
|
2013-02-27 |
2016-02-29 |
Epitherapeutics Aps |
Inhibitori ai histon-demetilazelor
|
JP2016512835A
(ja)
|
2013-03-15 |
2016-05-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤の組み合わせ及びそれらの使用
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
WO2014168986A1
(en)
|
2013-04-08 |
2014-10-16 |
Brown Dennis M |
Therapeutic benefit of suboptimally administered chemical compounds
|
EP2983661B1
(en)
|
2013-04-09 |
2024-05-29 |
Lixte Biotechnology, Inc. |
Formulations of oxabicycloheptanes and oxabicycloheptenes
|
RU2634694C2
(ru)
|
2013-04-29 |
2017-11-03 |
Чонг Кун Данг Фармасьютикал Корп. |
Новые соединения для селективных ингибиторов гистондеацетилазы и фармацевтическая композиция, включающая такие соединения
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
CN112472699A
(zh)
|
2013-07-26 |
2021-03-12 |
种族肿瘤学公司 |
改善比生群及衍生物的治疗益处的组合方法
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
EP3046563B1
(en)
|
2013-09-22 |
2019-05-29 |
Calitor Sciences, LLC |
Substituted aminopyrimidine compounds as pi3-kinase inhibitors
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
CN103467359B
(zh)
*
|
2013-09-27 |
2015-04-22 |
山东大学 |
一种含有吲哚的肉桂酰胺类组蛋白去乙酰化酶抑制剂及其制备方法和应用
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
CN103664734B
(zh)
*
|
2013-12-10 |
2015-09-23 |
广州康缔安生物科技有限公司 |
杂环羟肟酸类化合物及其药用组合物和应用
|
CN105940001B
(zh)
|
2013-12-12 |
2018-02-06 |
株式会社钟根堂 |
作为选择性组蛋白脱乙酰酶(hdac)抑制剂的新型氮杂吲哚衍生物及包含其的药物组合物
|
KR101685639B1
(ko)
|
2014-01-03 |
2016-12-12 |
주식회사 종근당 |
신규한 인돌 유도체 화합물 및 이를 포함하는 약제학적 조성물
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
ES2921874T3
(es)
|
2014-02-28 |
2022-09-01 |
Nimbus Lakshmi Inc |
Inhibidores de TYK2 y usos de los mismos
|
WO2015148714A1
(en)
|
2014-03-25 |
2015-10-01 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
CA2943979A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
AR099890A1
(es)
|
2014-03-31 |
2016-08-24 |
Epitherapeutics Aps |
Inhibidores de histona demetilasas
|
MX2016012893A
(es)
|
2014-04-03 |
2017-05-12 |
Invictus Oncology Pvt Ltd |
Sustancias terapéuticas combinadas supramoleculares.
|
KR20240038809A
(ko)
|
2014-04-14 |
2024-03-25 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
EP3174869B1
(en)
|
2014-07-31 |
2020-08-19 |
Novartis AG |
Combination therapy of a met inhibitor and an egfr inhibitor
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
US11311512B2
(en)
|
2014-08-12 |
2022-04-26 |
Monash University |
Lymph directing prodrugs
|
MX2017002451A
(es)
|
2014-08-27 |
2017-05-23 |
Gilead Sciences Inc |
Compuestos y metodos para inhibir histona desmetilasas.
|
EP2995630A1
(en)
|
2014-09-09 |
2016-03-16 |
Dublin Institute of Technology |
Hybrid compounds formed from ionic liquids and uses thereof in ion selective electrodes
|
WO2016040882A1
(en)
|
2014-09-13 |
2016-03-17 |
Novartis Ag |
Combination therapies of egfr inhibitors
|
CN107106687A
(zh)
|
2014-10-03 |
2017-08-29 |
诺华股份有限公司 |
组合治疗
|
TWI788655B
(zh)
|
2015-02-27 |
2023-01-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
MY190404A
(en)
|
2015-03-10 |
2022-04-21 |
Aduro Biotech Inc |
Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
|
EP3932914A1
(en)
|
2015-03-13 |
2022-01-05 |
Valo Health, Inc. |
Alpha-cinnamide compounds and compositions as hdac8 inhibitors
|
ES2776680T3
(es)
|
2015-05-22 |
2020-07-31 |
Chong Kun Dang Pharmaceutical Corp |
Compuestos derivados de heterocicloalquilo como inhibidores selectivos de histona desacetilasa y composiciones farmacéuticas que los comprenden
|
WO2017004133A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
CN108350062B
(zh)
|
2015-08-06 |
2022-10-14 |
达纳-法伯癌症研究所股份有限公司 |
靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应
|
WO2017032281A1
(zh)
*
|
2015-08-21 |
2017-03-02 |
苏州晶云药物科技有限公司 |
帕比司他乳酸盐的新晶型
|
EP4327809A3
(en)
|
2015-09-02 |
2024-04-17 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors and uses thereof
|
CN118063537A
(zh)
|
2015-09-08 |
2024-05-24 |
莫纳什大学 |
定向淋巴的前药
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
SI3364958T1
(sl)
|
2015-10-23 |
2023-05-31 |
Navitor Pharmaceuticals, Inc. |
Modulatorji interakcije sestrina in gator2 ter njihova uporaba
|
WO2017079267A1
(en)
|
2015-11-02 |
2017-05-11 |
Yale University |
Proteolysis targeting chimera compounds and methods of preparing and using same
|
ITUB20155193A1
(it)
|
2015-11-03 |
2017-05-03 |
Italfarmaco Spa |
Sospensioni orali di Givinostat fisicamente e chimicamente stabili
|
CN109069426B
(zh)
|
2015-12-14 |
2021-10-29 |
X4 制药有限公司 |
治疗癌症的方法
|
WO2017106332A1
(en)
|
2015-12-14 |
2017-06-22 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
US11370792B2
(en)
|
2015-12-14 |
2022-06-28 |
Raze Therapeutics, Inc. |
Caffeine inhibitors of MTHFD2 and uses thereof
|
EP3393468B1
(en)
|
2015-12-22 |
2022-09-14 |
X4 Pharmaceuticals, Inc. |
Methods for treating immunodeficiency disease
|
CN105732467A
(zh)
*
|
2016-01-13 |
2016-07-06 |
深圳市康立生生物科技有限公司 |
一种panobinostat(帕比司他)的制备方法
|
LT3426243T
(lt)
|
2016-03-09 |
2021-08-10 |
Raze Therapeutics, Inc. |
3-fosfogliceratdehidrogenazės inhibitoriai ir jų panaudojimas
|
EP3426244B1
(en)
|
2016-03-09 |
2023-06-07 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
EP3429570A1
(en)
|
2016-03-15 |
2019-01-23 |
Oryzon Genomics, S.A. |
Combinations of lsd1 inhibitors for the treatment of hematological malignancies
|
EP3429571A1
(en)
|
2016-03-15 |
2019-01-23 |
Oryzon Genomics, S.A. |
Combinations of lsd1 inhibitors for use in the treatment of solid tumors
|
US11337969B2
(en)
|
2016-04-08 |
2022-05-24 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
AR108257A1
(es)
|
2016-05-02 |
2018-08-01 |
Mei Pharma Inc |
Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
CN109562107A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的杂环降解决定子体
|
WO2017197036A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
EP3471726A4
(en)
|
2016-06-21 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
WO2017219083A1
(en)
*
|
2016-06-21 |
2017-12-28 |
The University Of Melbourne |
Activators of hiv latency
|
CA3027498A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
CN109641838A
(zh)
|
2016-06-21 |
2019-04-16 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
WO2018015493A1
(en)
|
2016-07-20 |
2018-01-25 |
Royal College Of Surgeons In Ireland |
Metal complexes having therapeutic applications
|
WO2018039205A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
WO2018054960A1
(en)
|
2016-09-21 |
2018-03-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting and treating resistance to chemotherapy in npm-alk(+) alcl
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
CA3040155C
(en)
|
2016-10-11 |
2024-01-16 |
Euro-Celtique S.A. |
Compound for use in the treatment of hodgkin lymphoma
|
US10323036B2
(en)
|
2016-10-14 |
2019-06-18 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
WO2018075937A1
(en)
|
2016-10-21 |
2018-04-26 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
US10414727B2
(en)
|
2016-11-08 |
2019-09-17 |
Navitor Pharmaceuticals, Inc. |
Phenyl amino piperidine mTORC inhibitors and uses thereof
|
EP4035659A1
(en)
|
2016-11-29 |
2022-08-03 |
PureTech LYT, Inc. |
Exosomes for delivery of therapeutic agents
|
WO2018106636A1
(en)
|
2016-12-05 |
2018-06-14 |
Raze Therapeutics, Inc. |
Shmt inhibitors and uses thereof
|
US11730819B2
(en)
|
2016-12-23 |
2023-08-22 |
Bicycletx Limited |
Peptide derivatives having novel linkage structures
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
JP7227912B2
(ja)
|
2017-02-08 |
2023-02-24 |
ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド |
キメラ抗原受容体の調節
|
TW202321243A
(zh)
|
2017-03-08 |
2023-06-01 |
美商林伯士拉克許米公司 |
Tyk2抑制劑之生產方法
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
JOP20180036A1
(ar)
|
2017-04-18 |
2019-01-30 |
Vifor Int Ag |
أملاح لمثبطات فروبورتين جديدة
|
WO2018197893A1
(en)
|
2017-04-27 |
2018-11-01 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
CN107141244B
(zh)
*
|
2017-05-08 |
2019-11-19 |
潍坊医学院 |
吲哚丁酸类组蛋白去乙酰酶抑制剂及其制备方法和应用
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
JP7301757B2
(ja)
|
2017-06-26 |
2023-07-03 |
バイスクルアールディー・リミテッド |
検出可能部分を持つ二環式ペプチドリガンドおよびその使用
|
MX2020001103A
(es)
|
2017-07-28 |
2020-08-17 |
Nimbus Lakshmi Inc |
Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
|
KR101977970B1
(ko)
|
2017-08-04 |
2019-05-14 |
중원대학교 산학협력단 |
신규한 벤즈아미드계 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 예방 또는 치료용 약학 조성물
|
US20200283482A1
(en)
|
2017-08-14 |
2020-09-10 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
US20200291096A1
(en)
|
2017-08-14 |
2020-09-17 |
Bicyclerd Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
AU2018338314A1
(en)
|
2017-09-22 |
2020-04-09 |
Kymera Therapeutics, Inc |
Protein degraders and uses thereof
|
EP3461480A1
(en)
|
2017-09-27 |
2019-04-03 |
Onxeo |
Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
|
EP3461488A1
(en)
|
2017-09-27 |
2019-04-03 |
Onxeo |
Combination of a dbait molecule and a hdac inhibitor for treating cancer
|
WO2019083962A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE AND PEMBROLIZUMAB VACCINES FOR THE TREATMENT OF BREAST CANCER
|
EP3700901A1
(en)
|
2017-10-24 |
2020-09-02 |
Genentech, Inc. |
(4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
AU2017444054B2
(en)
|
2017-12-21 |
2021-10-07 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
WO2019133531A1
(en)
|
2017-12-26 |
2019-07-04 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
US11512080B2
(en)
|
2018-01-12 |
2022-11-29 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADANTS AND USES THEREOF
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
WO2019148136A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
CN118005640A
(zh)
|
2018-01-29 |
2024-05-10 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
MX2020008417A
(es)
|
2018-02-12 |
2020-11-11 |
Inimmune Corp |
Ligandos de receptores de tipo toll.
|
AU2019229258B2
(en)
|
2018-02-27 |
2023-09-14 |
Artax Biopharma Inc. |
Chromene derivatives as inhibitors of TCR-Nck interaction
|
WO2019183523A1
(en)
|
2018-03-23 |
2019-09-26 |
Genentech, Inc. |
Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
|
IL310860A
(en)
|
2018-04-13 |
2024-04-01 |
Arvinas Operations Inc |
Servalon ligands and bifunctional compounds containing them
|
ES2969982T3
(es)
|
2018-04-24 |
2024-05-23 |
Vertex Pharma |
Compuestos de pteridinona y usos de los mismos
|
HUE058746T2
(hu)
|
2018-04-24 |
2022-09-28 |
Merck Patent Gmbh |
Antiproliferációs vegyületek és felhasználásuk
|
US11925690B2
(en)
|
2018-06-13 |
2024-03-12 |
Amphista Therapeutics Limited |
Bifunctional molecules for targeting Rpn11
|
WO2019238886A1
(en)
|
2018-06-13 |
2019-12-19 |
University Of Dundee |
Bifunctional molecules for targeting usp14
|
JP2021533181A
(ja)
|
2018-06-13 |
2021-12-02 |
アンフィスタ セラピューティクス リミテッド |
UchL5を標的化するための二機能性分子
|
EP3813946B1
(en)
|
2018-06-15 |
2024-05-22 |
Janssen Pharmaceutica NV |
Rapamycin analogs and uses thereof
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
EP3817748A4
(en)
|
2018-07-06 |
2022-08-24 |
Kymera Therapeutics, Inc. |
TRICYCLIC CRBN LIGANDS AND USES THEREOF
|
CN108752255A
(zh)
*
|
2018-07-19 |
2018-11-06 |
重庆医科大学 |
一种帕比司他及其关键中间体的制备方法
|
EP3826988A4
(en)
|
2018-07-24 |
2023-03-22 |
Hygia Pharmaceuticals, LLC |
COMPOUNDS, DERIVATIVES AND ANALOGS AGAINST CANCER
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
WO2020051424A1
(en)
|
2018-09-07 |
2020-03-12 |
Pic Therapeutics |
Eif4e inhibitors and uses thereof
|
EP3866789A4
(en)
|
2018-10-15 |
2022-07-06 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
JP2022512779A
(ja)
|
2018-10-23 |
2022-02-07 |
バイスクルテクス・リミテッド |
二環式ペプチドリガンドおよびその使用
|
CN109574936B
(zh)
*
|
2018-11-23 |
2022-02-22 |
沈阳药科大学 |
一种具有hdac6抑制活性的异羟肟酸类化合物及其应用
|
AU2019389174A1
(en)
|
2018-11-30 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
JP2022509260A
(ja)
|
2018-11-30 |
2022-01-20 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
EP3897631A4
(en)
|
2018-12-20 |
2022-11-23 |
C4 Therapeutics, Inc. |
TARGETED PROTEIN DEGRADATION
|
US11174264B2
(en)
|
2019-01-23 |
2021-11-16 |
Nimbus Lakshmi, Inc. |
TYK2 inhibitors and uses thereof
|
WO2020165600A1
(en)
|
2019-02-14 |
2020-08-20 |
Bicycletx Limited |
Bicyclic peptide ligand sting conjugates and uses thereof
|
WO2020201753A1
(en)
|
2019-04-02 |
2020-10-08 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
WO2020206424A1
(en)
|
2019-04-05 |
2020-10-08 |
Kymera Therapeutics, Inc. |
Stat degraders and uses thereof
|
CN114502540A
(zh)
|
2019-05-31 |
2022-05-13 |
医肯纳肿瘤学公司 |
Tead抑制剂和其用途
|
GB201913124D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
GB201913122D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
GB201913121D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
GB201913123D0
(en)
|
2019-09-11 |
2019-10-23 |
Seald As |
Compositions and methods for treatment of cholangiocarcinoma
|
EP4028385A4
(en)
|
2019-09-11 |
2023-11-08 |
Vincere Biosciences, Inc. |
USP30 INHIBITORS AND USES THEREOF
|
EP3798250A1
(en)
|
2019-09-25 |
2021-03-31 |
University College Dublin |
Hyperbranched cationic polymers useful as nucleic acid delivery vectors for transfecting
|
CN114650811A
(zh)
|
2019-09-25 |
2022-06-21 |
爱尔兰国立都柏林大学 |
用于基因疗法的纳米粒子组合物
|
EP4054546A4
(en)
*
|
2019-11-06 |
2023-10-18 |
Dana-Farber Cancer Institute, Inc. |
SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADATION PRODUCTS AND METHOD FOR THE USE THEREOF
|
JP2023506410A
(ja)
|
2019-12-05 |
2023-02-16 |
アナクリア セラピューティクス, インコーポレイテッド |
ラパマイシン類似体及びその使用
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
CA3161878A1
(en)
|
2019-12-17 |
2021-06-24 |
Matthew M. Weiss |
Irak degraders and uses thereof
|
MX2022007678A
(es)
|
2019-12-19 |
2022-09-19 |
Arvinas Operations Inc |
Compuestos y metodos para la degradacion dirigida del receptor de androgenos.
|
AU2020412780A1
(en)
|
2019-12-23 |
2022-07-21 |
Kymera Therapeutics, Inc. |
SMARCA degraders and uses thereof
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
IL295362A
(en)
|
2020-02-05 |
2022-10-01 |
Puretech Lyt Inc |
Lipid drug inhibitors of neurosteroids
|
IT202000004075A1
(it)
|
2020-02-27 |
2021-08-27 |
Flamma Spa |
Processo per la preparazione di panobinostat
|
CA3170411A1
(en)
|
2020-03-03 |
2021-09-10 |
Christopher L. Vandeusen |
Eif4e inhibitors and uses thereof
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
CA3171258A1
(en)
|
2020-03-19 |
2021-09-23 |
Nan JI |
Mdm2 degraders and uses thereof
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
WO2022029220A1
(en)
|
2020-08-05 |
2022-02-10 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
CN116234931A
(zh)
|
2020-08-17 |
2023-06-06 |
拜斯科技术开发有限公司 |
对nectin-4具有特异性的双环缀合物及其用途
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
KR20230131189A
(ko)
|
2020-12-02 |
2023-09-12 |
이케나 온콜로지, 인코포레이티드 |
Tead 억제제 및 이의 용도
|
IL303717A
(en)
|
2020-12-18 |
2023-08-01 |
Amphista Therapeutics Ltd |
New bifunctional molecules for directing protein degradation
|
GB202020359D0
(en)
|
2020-12-22 |
2021-02-03 |
Midatech Pharma Wales Ltd |
Pharmaceutical compositions and use thereof in combination therapy for brain cancer
|
KR20230153387A
(ko)
|
2021-02-02 |
2023-11-06 |
리미널 바이오사이언시스 리미티드 |
Gpr84 길항제 및 이의 용도
|
MX2023009059A
(es)
|
2021-02-02 |
2023-09-15 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 y usos de estos.
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
IL310924A
(en)
|
2021-08-25 |
2024-04-01 |
Pic Therapeutics Inc |
EIF4E inhibitors and their uses
|
WO2023028238A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
WO2023041805A1
(en)
|
2021-09-20 |
2023-03-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
|
GB2611043A
(en)
|
2021-09-22 |
2023-03-29 |
Univ Dublin City |
A cis-platinum(II)-oligomer hybrid
|
WO2023089183A1
(en)
|
2021-11-19 |
2023-05-25 |
Branca Bunus Limited |
A composition comprising a therapeutically active agent packaged within a drug delivery vehicle
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023194441A1
(en)
|
2022-04-05 |
2023-10-12 |
Istituto Nazionale Tumori Irccs - Fondazione G. Pascale |
Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
GB2617409A
(en)
|
2022-04-27 |
2023-10-11 |
Cancertain Ltd |
Method for predicting responsiveness to therapy
|
WO2023230205A1
(en)
|
2022-05-25 |
2023-11-30 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023242597A1
(en)
|
2022-06-16 |
2023-12-21 |
Amphista Therapeutics Limited |
Bifunctional molecules for targeted protein degradation
|
WO2024028363A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
|
WO2024028364A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|
WO2024028365A1
(en)
|
2022-08-02 |
2024-02-08 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
WO2024041744A1
(en)
|
2022-08-26 |
2024-02-29 |
Biodexa Ltd. |
Combination therapy for brain cancer
|